COST-EFFECTIVENESS OF VEDOLIZUMAB COMPARED WITH CONVENTIONAL THERAPY IN PATIENTS WITH CROHN'S DISEASE IN THE UNITED KINGDOM (UK)

被引：0
|
作者：
Robson, R. E. [1 ]
Vanoli, A. [2 ]
Tolley, K. [3 ]
机构：
[1] Tolley Hlth Econ, Buxton, England
[2] CEMOR Med Ltd, Newcastle Upon Tyne, Tyne & Wear, England
[3] Tolley Hlth Econ Ltd, Buxton, England
来源：
VALUE IN HEALTH | 2018年 / 21卷
关键词：
D O I：
10.1016/j.jval.2018.09.2689
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PSY114
引用
收藏
页码：S455 / S456
页数：3
相关论文
共 50 条
  • [1] COST-EFFECTIVENESS OF VEDOLIZUMAB VERSUS USTEKINUMAB IN UNITED KINGDOM CROHN'S DISEASE PATIENTS WHO PREVIOUSLY FAILED TNF INHIBITOR THERAPY
    Wilson, M.
    Lucas, A.
    VALUE IN HEALTH, 2018, 21 : S145 - S145
  • [2] COST-EFFECTIVENESS OF VEDOLIZUMAB COMPARED WITH USTEKINUMAB AS TREATMENT FOR PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN'S DISEASE IN THE UNITED STATES
    Zouraq, Azzabi, I
    Wilson, M.
    Hather, G.
    Curtis, R.
    Luo, M.
    Khalid, J. M.
    Minda, K.
    VALUE IN HEALTH, 2017, 20 (05) : A183 - A183
  • [3] COST-EFFECTIVENESS OF VEDOLIZUMAB COMPARED WITH CONVENTIONAL THERAPY FOR TREATMENT OF MODERATELY-TO-SEVERELY ACTIVE ULCERATIVE COLITIS IN THE UNITED KINGDOM
    Wilson, M.
    Kerrigan, M.
    Smyth, M.
    Chevrou-Severac, H.
    Bergman, A.
    Selby, R.
    GUT, 2016, 65 : A260 - A260
  • [4] Cost-effectiveness of vedolizumab compared with infliximab, adalimumab, and golimumab in patients with ulcerative colitis in the United Kingdom
    Wilson, Michele R.
    Bergman, Annika
    Chevrou-Severac, Helene
    Selby, Ross
    Smyth, Michael
    Kerrigan, Matthew C.
    EUROPEAN JOURNAL OF HEALTH ECONOMICS, 2018, 19 (02): : 229 - 240
  • [5] Cost-effectiveness of vedolizumab compared with infliximab, adalimumab, and golimumab in patients with ulcerative colitis in the United Kingdom
    Michele R. Wilson
    Annika Bergman
    Helene Chevrou-Severac
    Ross Selby
    Michael Smyth
    Matthew C. Kerrigan
    The European Journal of Health Economics, 2018, 19 : 229 - 240
  • [6] A MARKOV MODEL EVALUATING THE COST-EFFECTIVENESS OF USTEKINUMAB COMPARED TO VEDOLIZUMAB FOR PATIENT'S WITH CROHN'S DISEASE AS THIRD-LINE THERAPY
    Schneider, Yecheskel
    Saumoy, Monica
    Cohen-Mekelburg, Shirley A.
    Gold, Stephanie
    Scherl, Ellen
    Steinlauf, Adam F.
    GASTROENTEROLOGY, 2017, 152 (05) : S589 - S589
  • [7] Cost-effectiveness analysis of the use of visipaque compared to omnipaque in the United Kingdom (UK)
    Zyczynski, T.
    Beard, S.
    Earnshaw, S. R.
    McDade, C. L.
    VALUE IN HEALTH, 2007, 10 (06) : A419 - A419
  • [8] Cost-Effectiveness of Vedolizumab Compared to Adalimumab for Patients with Crohn's Disease Aft er Loss of Response to Infliximab: A Markov Model
    Schneider, Yecheskel
    Saumoy, Monica
    Gold, Stephanie L.
    Cohen-Mekelburg, Shirley
    Bosworth, Brian
    Scherl, Ellen J.
    Steinlauf, Adam
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2016, 111 : S335 - S336
  • [9] Cost-Effectiveness of Vedolizumab Compared With Conventional Therapy and Biologics for Treatment of Moderately to Severely Active Ulcerative Colitis in the United States
    Wilson, Michele
    Mody, Reema
    Ursan, Iulia
    Carr, Sean
    GASTROENTEROLOGY, 2015, 148 (04) : S198 - S199
  • [10] Effectiveness of Vedolizumab Therapy for Crohn's Disease
    Kessing, Richard
    ZEITSCHRIFT FUR GASTROENTEROLOGIE, 2019, 57 (12): : 1443 - 1443
12345